Steven Yukl, MD

Associate Professor In Res

Infectious Diseases

  1. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.
  2. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
  3. Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection.
  4. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
  5. Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency.
  6. Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate.
  7. Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
  8. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency.
  9. HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.
  10. HIV latency is reversed by ACSS2-driven histone crotonylation.
  11. Anatomic Compartments as a Barrier to HIV Cure.
  12. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
  13. An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies.
  14. Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.
  15. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals.
  16. Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals.
  17. Exploring HIV latency using transcription profiling.
  18. Assays for precise quantification of total (including short) and elongated HIV-1 transcripts.
  19. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
  20. Tissue reservoirs of HIV.
  21. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
  22. Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults.
  23. Anatomic Compartments as a Barrier to HIV Cure.
  24. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells.
  25. Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells.
  26. Decreased HIV type 1 transcription in CCR5-?32 heterozygotes during suppressive antiretroviral therapy.
  27. Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR.
  28. Discordance between peripheral and colonic markers of inflammation during suppressive ART.
  29. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells.
  30. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.
  31. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers.
  32. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence.
  33. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.
  34. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.
  35. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo.
  36. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.
  37. CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut.
  38. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
  39. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
  40. Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.
  41. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity.
  42. Blood and guts and HIV: preferential HIV persistence in GI mucosa.
  43. The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit.